Dr. Tibes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13400 E Shea Blvd
Scottsdale, AZ 85259Phone+1 480-301-8000
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2003 - 2006
NYU Grossman School of MedicineResidency, Internal Medicine, 2001 - 2003
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1999
Certifications & Licensure
NY State Medical License 2017 - 2020
AZ State Medical License 2006 - 2019
Clinical Trials
- Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome Start of enrollment: 2012 May 01
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Start of enrollment: 2012 Sep 01
- A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 26 citationsTranscriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.Raoul Tibes, James M Bogenberger
Frontiers in Oncology. 2019-12-12 - 32 citationsSafety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II studyAlessandro Rambaldi, Alessandra Iurlo, Alessandro M. Vannucchi, Richard Noble, Nikolas von Bubnoff
Leukemia. 2020-02-11 - 355 citationsSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyAlexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Mark R. Litzow
The Lancet. Oncology. 2017-08-01
Journal Articles
- E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain MetastasesMitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
Abstracts/Posters
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...Raoul Tibes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...Raoul Tibes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid LeukemiaRaoul Tibes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
Press Mentions
NYU Langone’s Blood & Marrow Transplant Program Expands ServicesAugust 20th, 2018
Shop TalkJanuary 5th, 2018- Shop TalkJanuary 5th, 2018
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
